<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04622605</url>
  </required_header>
  <id_info>
    <org_study_id>2017-004</org_study_id>
    <nct_id>NCT04622605</nct_id>
  </id_info>
  <brief_title>Hydrus Microstent and Lens Extraction for the Treatment of Primary Angle-Closure Glaucoma</brief_title>
  <official_title>Hydrus Microstent and Lens Extraction for the Treatment of Primary Angle-Closure Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asian Eye Institute</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ivantis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asian Eye Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective evaluation of the Hydrus Microstent for the treatment of Primary&#xD;
      Angle Closure (PAC) and Primary Angle Closure Glaucoma (PACG) with adjunctive cataract. A&#xD;
      total of 20 subjects will be successfully treated with one Hydrus device after completion of&#xD;
      cataract extraction with phacoemulsification followed by IOL replacement (HMS cohort), and 10&#xD;
      eyes will be treated with phacoemulsification cataract extraction and IOL replacement only&#xD;
      (PCS group). Since cataract surgery is standard of care for this condition, eligible fellow&#xD;
      eyes from the HMS cohort may be enrolled into the PCS group. To avoid selection bias in this&#xD;
      non-randomized study, the first 20 consecutive qualifying subjects will be treated with&#xD;
      Hydrus and the next 10 consecutive qualifying eyes will be treated with cataract surgery&#xD;
      only.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to assess the effectiveness of the Hydrus Microstent for&#xD;
      lowering intraocular pressure in patients with PAC or PACG. The addition of the Hydrus is&#xD;
      expected to lower IOP and medication dependency, and thus reduce the risk of progression of&#xD;
      glaucoma. The PCS group will provide a control group to assess the magnitude of the Hydrus&#xD;
      treatment effect on IOP, medications, and safety.&#xD;
&#xD;
      Upon successfully meeting the study inclusion/exclusion criteria at both the screening and&#xD;
      baseline visits, the subject will be scheduled for surgery. Follow up will be continued for 1&#xD;
      year post surgery, and will include assessments of the subject's IOP, ocular health, and&#xD;
      visual acuity status. Visits will be conducted at 1, 7, 30, 90, 180, and 365 days.&#xD;
&#xD;
      A 20% drop in IOP in response to therapy is considered clinically meaningful. The study&#xD;
      treatment will be considered successful if a patient can obtain this response in IOP using&#xD;
      the same or a fewer number of medications as pre-operative baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in IOP</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of subjects with &gt; or = 20% reduction of IOP while maintaining the same or fewer number of glaucoma medications compared with baseline, measured by Goldmann applanation tonometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in IOP</measure>
    <time_frame>12 months</time_frame>
    <description>Change in IOP compared to baseline IOP regardless of the number of glaucoma medications</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Primary Angle Closure Glaucoma</condition>
  <condition>Primary Angle Closure</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cataract extraction and intraocular lens placement with combined placement of glaucoma microstent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Trabecular bypass and Schlemm's canal stent</intervention_name>
    <description>ab interno Microstent placement after cataract surgery</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Hydrus Microstent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Pre-Operative Inclusion Criteria&#xD;
&#xD;
          1. Male and Female patients at least 40 years of age.&#xD;
&#xD;
          2. An operable age-related cataract with visual impairment or glare, eligible for&#xD;
             phacoemulsification.&#xD;
&#xD;
          3. Subjects with diagnosed primary angle-closure (PAC; defined as appositional or&#xD;
             synechial irido-trabecular contact of 90 degrees or more on gonionscopy) OR primary&#xD;
             angle-closure glaucoma (PACG; defined as PAC with documented glaucomatous optic&#xD;
             neuropathy and/or reproducible glaucomatous visual field defect), and on &gt; or = 1&#xD;
             glaucoma medication with IOP &gt; or = 21mmHg at both preoperative visits.&#xD;
&#xD;
          4. PAC or PACG subjects that are newly diagnosed, or unmedicated (newly diagnosed or&#xD;
             non-compliant patient not using medication for &gt; 30 days), with IOP &gt; or = 24mmHg at&#xD;
             both preoperative visits.&#xD;
&#xD;
        The subject is able to understand the requirements of the study and is willing to provide&#xD;
        written informed consent, follow study instructions, and comply with all study procedures.&#xD;
&#xD;
        Intraoperative Inclusion Critera&#xD;
&#xD;
          1. An intact and centered capsulorhexis.&#xD;
&#xD;
          2. An intact posterior capsular bag.&#xD;
&#xD;
          3. A well-centered IOL implant placed in the capsular bag.&#xD;
&#xD;
          4. A clear view and visualization of the angle with direct gonioscopy.&#xD;
&#xD;
          5. No evidence of zonular dehiscence/rupture (uncomplicated cataract extraction)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pseudophakia in the intended study eye&#xD;
&#xD;
          2. All forms of glaucoma other than primary angle-closure (i.e. all open-angle glaucoma&#xD;
             including primary open-angle, pseudoexfoliative, or pigmentary glaucoma; neovascular,&#xD;
             uveitic, traumatic, steroid induced, lens induced, or glaucoma associated with&#xD;
             increased episcleral venous pressure; congenital or developmental glaucoma).&#xD;
&#xD;
          3. Secondary angle-closure glaucoma&#xD;
&#xD;
          4. Advanced glaucoma, defined as visual field mean deviation worse than -15 dB, or&#xD;
             cup-to-disc ration &gt; or = 0.9.&#xD;
&#xD;
          5. Visual field depression within the central 5 degrees of fixation, on pattern deviation&#xD;
             probability plot.&#xD;
&#xD;
          6. Eyes with an anticipated need for incisional glaucoma surgery (e.g. trabeculectomy or&#xD;
             tube shunt) within the 12-month follow-up period.&#xD;
&#xD;
          7. Central corneal thickness &gt;620 or &lt;490 microns.&#xD;
&#xD;
          8. Axial length &lt; or = 19 mm (nanophthalmos).&#xD;
&#xD;
          9. Previous incisional glaucoma surgery in the study eye, including trabeculectomy, tube&#xD;
             shunt, and non-penetrating procedures such as deep sclerectomy, viscocanalostomy or&#xD;
             canaloplasty.&#xD;
&#xD;
         10. Plateau iris syndrome.&#xD;
&#xD;
         11. History of complicated intraocular surgery.&#xD;
&#xD;
         12. Previous MIGS surgery in the study eye.&#xD;
&#xD;
         13. Proliferative diabetic retinopathy.&#xD;
&#xD;
         14. Previous surgery for retinal detachment.&#xD;
&#xD;
         15. Clinically significant corneal dystrophy (e.g. Fuch's Dystrophy).&#xD;
&#xD;
         16. Best-corrected visual acuity in the fellow eye worse than 20/200.&#xD;
&#xD;
         17. Previous corneal surgery.&#xD;
&#xD;
         18. Previous refractive surgery.&#xD;
&#xD;
         19. Degenerative visual disorders such as exudative age-related macular degeneration.&#xD;
&#xD;
         20. Clinically significant ocular inflammation or infection within thirty days prior to&#xD;
             screening.&#xD;
&#xD;
         21. Uncontrolled systemic disease that in the opinion of the investigator would put the&#xD;
             subject's health at risk and/or prevent the subject from completing all study visits.&#xD;
&#xD;
         22. Pregnant or nursing females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Robert Edward T Ang, MD</last_name>
    <phone>+63288982020</phone>
    <email>angbobby@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asian Eye Institute</name>
      <address>
        <city>Makati City</city>
        <state>Metro Manila</state>
        <zip>1200</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Edward T Ang, MD</last_name>
      <phone>+63288982020</phone>
      <email>angbobby@hotmail.com</email>
    </contact>
    <contact_backup>
      <phone_ext>Ang</phone_ext>
      <email>angbobby@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Edward T Ang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asian Eye Institute</investigator_affiliation>
    <investigator_full_name>Robert Edward T. Ang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Angle-Closure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

